Neonatal Injectable Nutrition Bags Recalled for Lack of Sterility Validation
Central Admixture Pharmacy Services is recalling 132 bags of neonatal injectable nutrition due to unvalidated sterilization processes. The lack of sterility assurance creates potential infection risk for neonatal patients receiving these products.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a risk-of-harm product (injectable nutritional solution for neonates) where sterility cannot be assured due to unvalidated manufacturing processes. No illnesses or injuries have been reported. The absence of reported harm and the theoretical nature of the hazard support a High severity rating per the established rubric.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 132 bags of Neonatal TPN (Total Parenteral Nutrition) Starter Bags containing Amino Acids (trophamine) 3.5% / Dextrose 10% with low calcium and heparin. The recalled product is supplied in 250mL IV bags for intravenous administration to neonatal patients.
The recall was issued due to lack of validation data for the manufacturer's sterilization cycles. Without adequate validation, the manufacturer cannot assure that the product maintains sterility. Non-sterile intravenous products carry significant risk of microbial contamination and serious infection in susceptible neonatal patients.
The affected lots are: Lot# 36-260018 (expiration 8/19/2023) and Lot# 36-262155 (expiration 8/21/2023). These products were distributed nationwide in the USA. Healthcare facilities should identify and quarantine any remaining stock of these lot numbers.
Healthcare providers should cease use of affected bags immediately and contact Central Admixture Pharmacy Services, Inc. (located at 2200 South 43rd Avenue, Phoenix, AZ 85043) or the FDA for guidance on replacement products. No illnesses have been reported in connection with this recall.
The recalled product
- Product
- Neonatal TPN Starter Bag, Amino Acids (trophamine) 3.5% / Dextrose 10% with **low calcium** and HEPARIN, IV Bag, total volume = 250mL, Rx only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Pheonix, AZ 85043, NDC: 72196-0429-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Affected units
- 132
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot# 36-260018
- Exp 8/19/2023
- 36-262155
- Exp 8/21/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 32 recalled by Central Admixture Pharmacy Services, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 32 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services, Inc.
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15